The consequences of epigenetic drugs in the treatment of AML

The consequences of epigenetic drugs in the treatment of AML

VJHemOnc

3 years
1,027 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how epigenetic drugs may have a capacity to modulate the immune system post-transplant in acute myeloid leukemia (AML). By demethylating the FOXP3 promoter it may be able to accelerate Treg reconstitution post-allograft and thereby potentially suppressing graft versus host disease. Prof Craddock also discusses the clinical trial RICAZA (ISRCTN36825171) in which 40 patients post-transplant azacidine was well-tolerated. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland
Up Next Autoplay
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 13 hours
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 13 hours
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 13 hours
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 13 hours
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
0 Views
Cancer-News 13 hours
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 13 hours
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 2 days
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 3 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
10 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week